solid print increas visibl mt
legaci print organ growth bcr
acceler
note gain share legaci hypoderm needl
space dcb usag av access seem inflect
rais top-line bottom-line guidanc year
gross margin littl light
guidanc impli gross margin need step meaning
ep guidanc rais contempl pullthrough fx revenu
guid step bake conservat
frankli littl surpris see share
print part market understand dont
understand share under-perform group write
well-round solid print nearli segment come
back guidanc rang common
reason hear expect high given flu
benefit dx compani med-tech result strong
perspect today print increas confid
hit organ growth rang medium term along
mid teen ep compound-annual-growth-rate solid free cash flow convers
find share compel current level would buyer
share level rais price target
continu next page
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect object
report investor consid report singl factor make invest decis
note ev/ebitda multipl base fiscal period
flu favor fx driven weaken usd off-set hw us dispens final quarter
neg us dispens
growth driven strength vascular access/ includ pre-filled flush devic
neg bp us dispens
underli driven strong adopt pyxi es us infus growth ou
driven growth pen needl us trend emerg market driven time
tender anticip
increment market demand larg pharmaceut biotech custom high-pack
contribut sever flu season quarter
ytd basi bp flu
perform driven microbiolog bd molecular platform off-set kiestra
instal time
flu contribut bp growth quarter
pre-analyt face tough comp vs prior year neg impact product issu
resolv within quarter
saw strength drug-coat balloon ou growth biopsi product particularli china
urolog cirtic care
saw growth acut non-acut product
benefit time temperatur manag capit order
gross margin tailwind currenc
oper margin tailwind currenc expans
us driven predominantli impact flu
ou driven board strength across segment
develop market saw strength eu surgeri urolog critic diagnost system
emea driven infus dispos medic deliveri solut benefit diabet
compar sale growth fxn compar sale growth foreign exchang
neutral basi exclud divestitur includ bcr prior period
underli sale growth fxn underli sale growth foreign exchang
neutral basi exclud divestitur account chang us dispens hurrican impact
includ bcr prior period
bd medic fxn chang versu last guidanc
bd intervent note appl appl comparison bcr product line
shift exclud hurrican impact fxn
foreign exchang tailwind tailwind ep includ bard
assum eur usd rate
oper margin expans
ep denot constant currenc growth
report growth approxim
interest net mm
synergi reaffirm expect mm fy split evenli follow
phase function system transform
phase long term project includ ration manufactur facil distribut
end gross leverag
paid mm debt
remain commit gross leverag within year
evercor isi medic suppli devicesbecton dickinson stat million except per share data fy end septemb organ gp less op less ep share inc net inc price-to-earnings multipl prem disc may
valuat methodolog base mix discount cash flow analysi rel valuat multipl
integr risk relat bcr transact potenti headwind corpor tax reform weak
articl articl
time dissemin may et
analyst vijay kumar primarili respons prepar research report attest follow view opinion
render research report reflect person view subject compani issuer part research
analyst compens directli relat specif recommend view research report
